Navigation Links
AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com
Date:11/23/2007

TUSTIN, Calif., Nov. 23 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL - News), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. The Company announced today that the recent presentation by its CEO, Gary Dreher, at the prestigious 9th Annual Healthcare Conference sponsored by the full-service investment bank, Rodman & Renshaw, and its life science division, Acumen BioFin,(TM) is now available at WallStreetRepoter.com.

The link to listen to the presentation is at http://www.wallstreetreporter.com/page.php?page=view_videos&id=134

Mr. Dreher noted that "AMDL recently announced that it had sales of approximately $5.8 million for the third quarter of 2007 compared to $2.3 million for the second quarter of 2007 with $0.05 per share in earnings. AMDL's introduction of new products and increased distribution channels caused the upturn in revenues and profits. This marked AMDL's first quarter with positive cash flow and net earnings. These superior results indicate that we anticipate that our Chinese subsidiaries will continue to experience strong sales and gross profit growth that will greatly improve AMDL's combined operating results."

About JPI: Jade Pharmaceutical has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com .

Contact: AMDL, Inc.

Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont ... today that they have entered into a multiyear collaboration to identify and characterize ... with additional tools for gene editing across all applications. , Under the terms ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):